Azenta Finalizes Sale of B Medical Systems to Thelema S.à r.l.

Azenta Finalizes Acquisition of B Medical Systems

Burlington, MA - July 8, 2026 - In a significant move to streamline its portfolio, Azenta, Inc., a prominent player in life sciences solutions, has announced the successful completion of the sale of its B Medical Systems division to Thelema S.à r.l. This transaction marks a pivotal moment in Azenta's evolution, following an earlier announcement on December 29, 2025, and the closure of the deal on July 1, 2026.

The agreement specified a fixed purchase price of $63 million in cash, with $35 million facilitated through a short-term secured vendor loan sourced from an Azenta subsidiary. John Marotta, Azenta’s CEO, emphasized that this divestiture not only simplifies the company’s focus on its vital life sciences operations but also provides enhanced financial flexibility necessary for growth strategies.

"This completion enhances our strategic positioning," stated Marotta. "By concentrating our resources on core growth platforms, we aim to drive sustained growth and bolster long-term value for our stakeholders."

Azenta Life Sciences is renowned worldwide, providing cutting-edge life science solutions that help organizations expedite their breakthroughs and therapies. Their extensive portfolio includes reliable cold-chain sample management solutions and multiomics services that span various sectors, including drug development, clinical research, and advanced cell therapies. Clients range from top pharmaceutical companies to academic institutions and healthcare organizations globally.

With strong operations in North America, Europe, and Asia, Azenta leverages its global reach to deliver superior products and services through industry-leading brands such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

The completion of this sale allows Azenta to concentrate further on its strategic priorities, as outlined in its recent filings with the Securities and Exchange Commission. In today's dynamic market, focusing on enhancing shareholder value while navigating forward-looking opportunities remains paramount.

In conclusion, the successful transaction and subsequent shift in strategy underscores Azenta’s commitment to delivering high-value solutions while positioning itself for future growth in the rapidly evolving life sciences industry. Stakeholders can expect continued innovation as Azenta aligns its resources to core business areas that promise long-term benefits and expansion.

For further information regarding Azenta's innovative solutions or to explore partnership opportunities, please visit their official website at www.azenta.com. Stay tuned for more updates as Azenta embarks on this new chapter with renewed focus and determination.